Stockwatch: All that glisters is not predictable
This article was originally published in Scrip
Executive Summary
Dendreon’s restructuring announced on September 8, came after the disappointing second quarter sales of its bespoke prostate cancer vaccine Provenge (sipuelcel-T) which also resulted in the company’s sales guidance for the year being withdrawn (scripintelligence.com, 8 September 2011). It now appears that Dendreon’s woes might be a wake-up call, not just for investors who are also watching new product launches this year from other companies, but also the Securities and Exchange Commission (SEC) on disclosure policies and so-called black-out periods when company management is prevented from selling stock.